Blood brain barrier: A challenge for effectual therapy of brain tumors

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Bhowmik, Arijit ^a   Khan, Rajni ^a   Ghosh, Mrinal Kanti ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CLAUDIN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; JUNCTIONAL ADHESION MOLECULE; LIPOSOME; LOMUSTINE; METHOTREXATE; MONOCARBOXYLATE TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; OCCLUDIN; ORGANIC ANION TRANSPORTER; PACLITAXEL; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ASTROCYTE; ASTROCYTOMA; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER PROGNOSIS; CRANIOPHARYNGIOMA; DRUG DELIVERY SYSTEM; ENDOTHELIUM; EPENDYMOMA; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HUMAN; MENINGIOMA; NEOPLASM; NEURILEMOMA; NONHUMAN; OLIGODENDROGLIOMA; PERICYTE; PILOCYTIC ASTROCYTOMA; PINEAL BODY TUMOR; RECURRENCE RISK; REVIEW; ACTIVE TRANSPORT; BRAIN NEOPLASMS; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; HUMANS;

EID: 84926482909     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/320941     Document Type: Review

References (261)

1. N.A. Vick, J.D. Khandekar, and D.D. Bigner, "Chemotherapy of brain tumors: the "blood-brain barrier" is not a factor," Archives of Neurology, vol. 34, no. 9, pp. 523-526, 1977.
2. M. G. Donelli, M. Zucchetti, and M. D'Incalci, "Do anticancer agents reach the tumor target in the human brain?" Cancer Chemotherapy and Pharmacology, vol. 30, no. 4, pp. 251-260, 1992.
3. W. M. Pardridge, "CNS drug design based on principles of blood-brain barrier transport," Journal of Neurochemistry, vol. 70, no. 5, pp. 1781-1792, 1998.
4. S. I. Rapoport, "Modulation of blood-brain barrier permeability," Journal of Drug Targeting, vol. 3, no. 6, pp. 417-425, 1996.
5. A. Tsuji and I. Tamai, "Sodium- and chloride-dependent transport of taurine at the blood-brain barrier," Advances in Experimental Medicine and Biology, vol. 403, pp. 385-391, 1996.
6. D. R. Groothuis, "The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery," Neuro-Oncology, vol. 2, no. 1, pp. 45-49, 2000.
7. D. R. Groothuis, F. J. Vriesendorp, B. Kupfer et al., "Quantitative measurements of capillary transport in human brain tumors by computed tomography," Annals of Neurology, vol. 30, no. 4, pp. 581-588, 1991.
8. D. M. Long, "Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors," Journal of Neurosurgery, vol. 32, no. 2, pp. 127-144, 1970.
9. S. Liebner, A. Fischmann, G. Rascher et al., "Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme," Acta Neuropathologica, vol. 100, no. 3, pp. 323-331, 2000.
10. S. Liebner, U. Kniesel, H. Kalbacher, and H. Wolburg, "Correlation of tight junction morphology with the expression of tight junction proteins in blood-brain barrier endothelial cells," European Journal of Cell Biology, vol. 79, no. 10, pp. 707-717, 2000.
11. M. C. Papadopoulos, S. Saadoun, C. J. Woodrow et al., "Occludin expression in microvessels of neoplastic and non-neoplastic human brain," Neuropathology and Applied Neurobiology, vol. 27, no. 5, pp. 384-395, 2001.
12. K. Lamszus, J. Laterra, M. Westphal, and E. M. Rosen, "Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas," International Journal of Developmental Neuroscience, vol. 17, no. 5-6, pp. 517-530, 1999.
13. M. W. Pitz, A. Desai, S. A. Grossman, and J. O. Blakeley, "Tissue concentration of systemically administered antineoplastic agents in human brain tumors," Journal of Neuro-Oncology, vol. 104, no. 3, pp. 629-638, 2011.
14. L. Rosso, C. S. Brock, J. M. Gallo et al., "A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients," Cancer Research, vol. 69, no. 1, pp. 120-127, 2009.
15. R. L. Fine, J. Chen, C. Balmaceda et al., "Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors," Clinical Cancer Research, vol. 12, no. 19, pp. 5770-5776, 2006.
16. C. Meewes, K. H. Bohuslavizki, B. Krisch, J. Held-Feindt, E. Henze, and M. Clausen, "Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas," Journal of Nuclear Medicine, vol. 42, no. 9, pp. 1338-1345, 2001.
17. S. Ammoun and C. O. Hanemann, "Emerging therapeutic targets in schwannomas and other merlin-deficient tumors," Nature Reviews Neurology, vol. 7, no. 7, pp. 392-399, 2011.
18. S. Fakhran and E. J. Escott, "Pineocytoma mimicking a pineal cyst on imaging: true diagnostic dilemma or a case of incomplete imaging?" The American Journal of Neuroradiology, vol. 29, no. 1, pp. 159-163, 2008.
19. T. S. Reese and M. J. Karnovsky, "Fine structural localization of a blood-brain barrier to exogenous peroxidase," The Journal of Cell Biology, vol. 34, no. 1, pp. 207-217, 1967.
20. M. W. Brightman and T. S. Reese, "Junctions between intimately apposed cell membranes in the vertebrate brain," Journal of Cell Biology, vol. 40, no. 3, pp. 648-677, 1969.
21. P. A. Stewart and M. J. Wiley, "Structural and histochemical features of the avian blood-brain barrier," Journal of Comparative Neurology, vol. 202, no. 2, pp. 157-167, 1981.
22. A. W. Vorbrodt and D. H. Dobrogowska, "Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view," Brain Research Reviews, vol. 42, no. 3, pp. 221-242, 2003.
23. B. V. Zlokovic, "The blood-brain barrier in health and chronic neurodegenerative disorders," Neuron, vol. 57, no. 2, pp. 178-201, 2008.
24. B. T. Hawkins and T. P. Davis, "The blood-brain barrier/neurovascular unit in health and disease," Pharmacological Reviews, vol. 57, no. 2, pp. 173-185, 2005.
25. R. A. Hawkins, R. L. O'Kane, I. A. Simpson, and J. R. Viña, "Structure of the blood-brain barrier and its role in the transport of amino acids," Journal of Nutrition, vol. 136, supplement 1, pp. 218S-226S, 2006.
26. A. M. Butt, H. C. Jones, and N. J. Abbott, "Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study," Journal of Physiology, vol. 429, pp. 47-62, 1990.
27. P. T. Ronaldson and T. P. Davis, "Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke," Current Pharmaceutical Design, vol. 18, no. 25, pp. 3624-3644, 2012.
28. N. J. Abbott, L. Rönnbäck, and E. Hansson, "Astrocyte-endothelial interactions at the blood-brain barrier," Nature Reviews Neuroscience, vol. 7, no. 1, pp. 41-53, 2006.
29. A. Armulik, G. Genové, M. Mäe et al., "Pericytes regulate the blood-brain barrier," Nature, vol. 468, no. 7323, pp. 557-561, 2010.
30. H. Kimelberg, T. Jalonen, and W. Walz, "Regulation of brain microenvironment: transmitters and ions," in Astrocytes: Pharmacology and Function, S. Murphy, Ed., pp. 193-222, Academic Press, San Diego, Calif, USA, 1993.
31. M. Nuriya, T. Shinotsuka, and M. Yasui, "Diffusion properties of molecules at the blood-brain interface: potential contributions of astrocyte endfeet to diffusion barrier functions," Cerebral Cortex, vol. 23, no. 9, pp. 2118-2126, 2013.
32. T. M. Mathiisen, K. P. Lehre, N. C. Danbolt, and O. P. Ottersen, "The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction," Glia, vol. 58, no. 9, pp. 1094-1103, 2010.
33. M. Furuse, T. Hirase, M. Itoh, A. Nagafuchi, S. Yonemura, and S. Tsukita, "Occludin: a novel integral membrane protein localizing at tight junctions," Journal of Cell Biology, vol. 123, no. 6, pp. 1777-1788, 1993.
34. Y. Ando-Akatsuka, M. Saitou, T. Hirase et al., "Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues," Journal of Cell Biology, vol. 133, no. 1, pp. 43-47, 1996.
35. R. Rao, "Occludin phosphorylation in regulation of epithelial tight junctions," Annals of the New York Academy of Sciences, vol. 1165, pp. 62-68, 2009.
36. J. Piontek, L. Winkler, H. Wolburg et al., "Formation of tight junction: determinants of homophilic interaction between classic claudins," The FASEB Journal, vol. 22, no. 1, pp. 146-158, 2008.
37. M. Itoh, M. Furuse, K. Morita, K. Kubota, M. Saitou, and S. Tsukita, "Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins," The Journal of Cell Biology, vol. 147, no. 6, pp. 1351-1363, 1999.
38. K. Matter and M. S. Balda, "Holey barrier: claudins and the regulation of brain endothelial permeability," The Journal of Cell Biology, vol. 161, no. 3, pp. 459-460, 2003.
39. T. Nitta, M. Hata, S. Gotoh et al., "Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice," Journal of Cell Biology, vol. 161, no. 3, pp. 653-660, 2003.
40. A. Schrade, H. Sade, P.-O. Couraud, I. A. Romero, B. B. Weksler, and J. Niewoehner, "Expression and localization of claudins-3 and -12 in transformed human brain endothelium," Fluids and Barriers of the CNS, vol. 9, no. 1, article 6, 2012.
41. M. Aurrand-Lions, C. Johnson-Leger, C. Wong, L. Du Pasquier, and B. A. Imhof, "Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members," Blood, vol. 98, no. 13, pp. 3699-3707, 2001.
42. G. Gliki, K. Ebnet, M. Aurrand-Lions, B. A. Imhof, and R. H. Adams, "Spermatid differentiation requires the assembly of a cell polarity complex downstream of junctional adhesion molecule-C," Nature, vol. 431, no. 7006, pp. 320-324, 2004.
43. K. Ebnet, A. Suzuki, S. Ohno, and D. Vestweber, "Junctional adhesion molecules (JAMs): more molecules with dual functions?" Journal of Cell Science, vol. 117, part 1, pp. 19-29, 2004.
44. J. Haskins, L. Gu, E. S. Wittchen, J. Hibbard, and B. R. Stevenson, "ZO-3, a novel member of the MAGUK protein family found at the tight junction, interacts with ZO-1 and occludin," The Journal of Cell Biology, vol. 141, no. 1, pp. 199-208, 1998.
45. H. Fischer, R. Gottschlich, and A. Seelig, "Blood-brain barrier permeation: molecular parameters governing passive diffusion," Journal of Membrane Biology, vol. 165, no. 3, pp. 201-211, 1998.
46. L. M. Roberts, D. S. Black, C. Raman et al., "Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation," Neuroscience, vol. 155, no. 2, pp. 423-438, 2008.
47. M. Uldry and B. Thorens, "The SLC2 family of facilitated hexose and polyol transporters," Pflügers Archiv, vol. 447, no. 5, pp. 480-489, 2004.
48. M. Simionescu, A. Gafencu, and F. Antohe, "Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey," Microscopy Research and Technique, vol. 57, no. 5, pp. 269-288, 2002.
49. A. M. Wolka, J. D. Huber, and T. P. Davis, "Pain and the blood-brain barrier: obstacles to drug delivery," Advanced Drug Delivery Reviews, vol. 55, no. 8, pp. 987-1006, 2003.
50. L. B. Thomsen, J. Lichota, T. N. Eskehave et al., "Brain delivery systems via mechanism independent of receptor-mediated endocytosis and adsorptive-mediated endocytosis," Current Pharmaceutical Biotechnology, vol. 13, no. 12, pp. 2349-2354, 2012.
51. N. J. Abbott and I. A. Romero, "Transporting therapeutics across the blood-brain barrier," Molecular Medicine Today, vol. 2, no. 3, pp. 106-113, 1996.
52. G. Lee, S. Dallas, M. Hong, and R. Bendayan, "Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations," Pharmacological Reviews, vol. 53, no. 4, pp. 569-596, 2001.
53. D. J. Begley, "ABC transporters and the blood-brain barrier," Current Pharmaceutical Design, vol. 10, no. 12, pp. 1295-1312, 2004.
54. K. Moitra, "ABC transporters in human disease," Colloquium Series on The Genetic Basis of Human Disease, vol. 1, no. 1, pp. 1-84, 2012.
55. F. J. Sharom, "ABC multidrug transporters: structure, function and role in chemoresistance," Pharmacogenomics, vol. 9, no. 1, pp. 105-127, 2008.
56. K. Hollenstein, R. J. Dawson, and K. P. Locher, "Structure and mechanism of ABC transporter proteins," Current Opinion in Structural Biology, vol. 17, no. 4, pp. 412-418, 2007.
57. V. Ling and L. H. Thompson, "Reduced permeability in CHO cells as a mechanism of resistance to colchicine," Journal of Cellular Physiology, vol. 83, no. 1, pp. 103-116, 1974.
58. M. M. Gottesman, C. A. Hrycyna, P. V. Schoenlein, U. A. Germann, and I. Pastan, "Genetic analysis of the multidrug transporter," Annual Review of Genetics, vol. 29, pp. 607-649, 1995.
59. C.-J. Chen, J. E. Chin, K. Ueda et al., "Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells," Cell, vol. 47, no. 3, pp. 381-389, 1986.
60. I. B. Roninson, J. E. Chin, K. Choi et al., "Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 12, pp. 4538-4542, 1986.
61. L. Sanchez-Covarrubias, L. M. Slosky, B. J. Thompson et al., "P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac," PLoS ONE, vol. 9, no. 2, Article ID e88516, 2014.
62. T. W. Loo and D. M. Clarke, "P-glycoprotein: Associations between domains and between domains and molecular chaperones," Journal of Biological Chemistry, vol. 270, no. 37, pp. 21839-21844, 1995.
63. R. Bendayan, P. T. Ronaldson, D. Gingras, and M. Bendayan, "In situ localization of P-glycoprotein (ABCB1) in human and rat brain," Journal of Histochemistry and Cytochemistry, vol. 54, no. 10, pp. 1159-1167, 2006.
64. V. V. Rao, J. L. Dahlheimer, M. E. Bardgett et al., "Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3900-3905, 1999.
65. T. Litman, T. Zeuthen, T. Skovsgaard, and W. D. Stein, "Competitive, non-competitive and cooperative interactions between substrates of P-glycoproteins as measured by ATPase activity," Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1361, no. 2, pp. 169-176, 1997.
66. Y.-N. Chen, L. A. Mickley, A. M. Schwartz, E. M. Acton, J. Hwang, and A. T. Fojo, "Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein," The Journal of Biological Chemistry, vol. 265, no. 17, pp. 10073-10080, 1990.
67. L. A. Doyle, W. Yang, L. V. Abruzzo et al., "A multidrug resistance transporter from human MCF-7 breast cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15665-15670, 1998.
68. K. Mohrmann, M. A. J. van Eijndhoven, A. H. Schinkel, and J. H. M. Schellens, "Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2)," Cancer Chemotherapy and Pharmacology, vol. 56, no. 4, pp. 344-350, 2005.
69. T. Nakanishi, L. A. Doyle, B. Hassel et al., "Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis," Molecular Pharmacology, vol. 64, no. 6, pp. 1452-1462, 2003.
70. G. Lee, K. Babakhanian, M. Ramaswamy, A. Prat, K. Wosik, and R. Bendayan, "Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems," Pharmaceutical Research, vol. 24, no. 7, pp. 1262-1274, 2007.
71. T. Eisenblätter, S. Hüwel, and H.-J. Galla, "Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier," Brain Research, vol. 971, no. 2, pp. 221-231, 2003.
72. W. Zhang, J. Mojsilovic-Petrovic, M. F. Andrade, H. Zhang, M. Ball, and D. B. Stanimirovic, "The expression and functional characterization of ABCG2 in brain endothelial cells and vessels," The FASEB Journal, vol. 17, no. 14, pp. 2085-2087, 2003.
73. Q. Mao and J. D. Unadkat, "Role of the breast cancer resistance protein (ABCG2) in drug transport," The AAPS Journal, vol. 7, no. 1, pp. E118-E133, 2005.
74. F. Staud and P. Pavek, "Breast cancer resistance protein (BCRP/ABCG2)," The International Journal of Biochemistry & Cell Biology, vol. 37, no. 4, pp. 720-725, 2005.
75. D. D. Ross, W. Yang, L. V. Abruzzo et al., "Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines," Journal of the National Cancer Institute, vol. 91, no. 5, pp. 429-433, 1999.
76. K. Miyake, L. Mickley, T. Litman et al., "Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes," Cancer Research, vol. 59, no. 1, pp. 8-13, 1999.
77. A. T. Nies, G. Jedlitschky, J. König et al., "Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain," Neuroscience, vol. 129, no. 2, pp. 349-360, 2004.
78. H. Bronger, J. König, K. Kopplow et al., "ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier," Cancer Research, vol. 65, no. 24, pp. 11419-11428, 2005.
79. D. S. Miller, S. N. Nobmann, H. Gutmann, M. Toeroek, J. Drewe, and G. Fricker, "Xenobiotic transport across isolated brain microvessels studied by confocal microscopy," Molecular Pharmacology, vol. 58, no. 6, pp. 1357-1367, 2000.
80. P. Borst, R. Evers, M. Kool, and J. Wijnholds, "A family of drug transporters: the multidrug resistance-associated proteins," Journal of the National Cancer Institute, vol. 92, no. 16, pp. 1295-1302, 2000.
81. S. Dallas, D. S. Miller, and R. Bendayan, "Multidrug resistance-associated proteins: expression and function in the central nervous system," Pharmacological Reviews, vol. 58, no. 2, pp. 140-161, 2006.
82. Y.-J. Lee, H. Kusuhara, and Y. Sugiyama, "Do multidrug resistance-associated protein-1 and -2 play any role in the elimination of estradiol-17 β-glucuronide and 2,4-dinitrophenyl-S-glutathione across the blood-cerebrospinal fluid barrier?" Journal of Pharmaceutical Sciences, vol. 93, no. 1, pp. 99-107, 2004.
83. H. Kusuhara and Y. Sugiyama, "Active efflux across the blood-brain barrier: role of the solute carrier family," NeuroRx, vol. 2, no. 1, pp. 73-85, 2005.
84. M. A. Hediger, M. F. Romero, J.-B. Peng, A. Rolfs, H. Takanaga, and E. A. Bruford, "The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins," Pflugers Archiv European Journal of Physiology, vol. 447, no. 5, pp. 465-468, 2004.
85. M. Molina-Arcas, F. J. Casado, and M. Pastor-Anglada, "Nucleoside transporter proteins," Current Vascular Pharmacology, vol. 7, no. 4, pp. 426-434, 2009.
86. H. Daniel and G. Kottra, "The proton oligopeptide cotrans-porter family SLC15 in physiology and pharmacology," Pflügers Archiv, vol. 447, no. 5, pp. 610-618, 2004.
87. D. Herrera-Ruiz and G. T. Knipp, "Current perspectives on established and putative mammalian oligopeptide transporters," Journal of Pharmaceutical Sciences, vol. 92, no. 4, pp. 691-714, 2003.
88. S. M. Carl, D. J. Lindley, D. Das et al., "ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood-brain barrier cell line, hCMEC/D3 [corrected]," Molecular Pharmaceutics, vol. 7, no. 4, pp. 1057-1068, 2010.
89. D. E. Smith, C. E. Johanson, and R. F. Keep, "Peptide and peptide analog transport systems at the blood-CSF barrier," Advanced Drug Delivery Reviews, vol. 56, no. 12, pp. 1765-1791, 2004.
90. W. A. Banks and A. J. Kastin, "Brain-to-blood transport of peptides and the alcohol withdrawal syndrome," Annals of the New York Academy of Sciences, vol. 739, pp. 108-118, 1994.
91. A. P. Halestrap and M. C. Wilson, "The monocarboxylate transporter family-role and regulation," IUBMB Life, vol. 64, no. 2, pp. 109-119, 2012.
92. B. E. Enerson and L. R. Drewes, "Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery," Journal of Pharmaceutical Sciences, vol. 92, no. 8, pp. 1531-1544, 2003.
93. K. Pierre and L. Pellerin, "Monocarboxylate transporters in the central nervous system: distribution, regulation and function," Journal of Neurochemistry, vol. 94, no. 1, pp. 1-14, 2005.
94. A. Ceballos, M. M. Belinchon, E. Sanchez-Mendoza et al., "Importance of monocarboxylate transporter 8 for the blood-brain barrier-dependent availability of 3,5,3'-triiodo-L-thyronine," Endocrinology, vol. 150, no. 5, pp. 2491-2496, 2009.
95. S. Bröer, B. Rahman, G. Pellegri et al., "Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons," Journal of Biological Chemistry, vol. 272, no. 48, pp. 30096-30102, 1997.
96. L. Pellerin, A. P. Halestrap, and K. Pierre, "Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain," Journal of Neuroscience Research, vol. 79, no. 1-2, pp. 55-64, 2005.
97. M. Niemi, "Role of OATP transporters in the disposition of drugs," Pharmacogenomics, vol. 8, no. 7, pp. 787-802, 2007.
98. T. Mikkaichi, T. Suzuki, M. Tanemoto, S. Ito, and T. Abe, "The organic anion transporter (OATP) family," Drug Metabolism and Pharmacokinetics, vol. 19, no. 3, pp. 171-179, 2004.
99. B. Hagenbuch and P. J. Meier, "Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO super-family, new nomenclature and molecular/functional properties," Pflugers Archiv European Journal of Physiology, vol. 447, no. 5, pp. 653-665, 2004.
100. J. König, A. Seithel, U. Gradhand, and M. F. Fromm, "Pharmacogenomics of human OATP transporters," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 372, no. 6, pp. 432-443, 2006.
101. G. A. Kullak-Ublick, B. Hagenbuch, B. Stieger et al., "Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver," Gastroenterology, vol. 109, no. 4, pp. 1274-1282, 1995.
102. W. Lee, H. Glaeser, L. H. Smith et al., "Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry," The Journal of Biological Chemistry, vol. 280, no. 10, pp. 9610-9617, 2005.
103. M. Roth, A. Obaidat, and B. Hagenbuch, "OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies," British Journal of Pharmacology, vol. 165, no. 5, pp. 1260-1287, 2012.
104. R. D. Huber, B. Gao, M.-A. S. Pfändler et al., "Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain," American Journal of Physiology: Cell Physiology, vol. 292, no. 2, pp. C795-C806, 2007.
105. G. A. Baldeshwiler, A Structure Function Study of Organic Anion Transporting Polypeptide 1c1 (Oatp1c1), 2011.
106. J. W. Jonker and A. H. Schinkel, "Pharmacological and physiological functions of the polyspecific organic cation transporters: oct1, 2, and 3 (SLC22A1-3)," Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 1, pp. 2-9, 2004.
107. H. Kusuhara, T. Sekine, N. Utsunomiya-Tate et al., "Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain," The Journal of Biological Chemistry, vol. 274, no. 19, pp. 13675-13680, 1999.
108. S. H. Cha, T. Sekine, H. Kusuhara et al., "Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta," Journal of Biological Chemistry, vol. 275, no. 6, pp. 4507-4512, 2000.
109. T. Sekine, N. Watanabe, M. Hosoyamada, Y. Kanai, and H. Endou, "Expression cloning and characterization of a novel multispecific organic anion transporter," The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18526-18529, 1997.
110. D. H. Sweet and J. B. Pritchard, "The molecular biology of renal organic anion and organic cation transporters," Cell Biochemistry and Biophysics, vol. 31, no. 1, pp. 89-118, 1999.
111. J. C. Monte, M. A. Nagle, S. A. Eraly, and S. K. Nigam, "Identification of a novel murine organic anion transporter family member, OAT6, expressed in olfactory mucosa," Biochemical and Biophysical Research Communications, vol. 323, no. 2, pp. 429-436, 2004.
112. T. Sekine, S. H. Cha, and H. Endou, "The multispecific organic anion transporter (OAT) family," Pflügers Archiv, vol. 440, no. 3, pp. 337-350, 2000.
113. A. E. Riedmaier, A. T. Nies, E. Schaeffeler, and M. Schwab, "Organic anion transporters and their implications in pharmacotherapy," Pharmacological Reviews, vol. 64, no. 3, pp. 421-449, 2012.
114. S. Mori, H. Takanaga, S. Ohtsuki et al., "Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells," Journal of Cerebral Blood Flow and Metabolism, vol. 23, no. 4, pp. 432-440, 2003.
115. D. H. Sweet, D. S. Miller, J. B. Pritchard, Y. Fujiwara, D. R. Beier, and S. K. Nigam, "Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice," The Journal of Biological Chemistry, vol. 277, no. 30, pp. 26934-26943, 2002.
116. T. Sekine, S. H. Cha, M. Tsuda et al., "Identification of multi-specific organic anion transporter 2 expressed predominantly in the liver," FEBS Letters, vol. 429, no. 2, pp. 179-182, 1998.
117. G. L. Youngblood and D. H. Sweet, "Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney," The American Journal of Physiology-Renal Physiology, vol. 287, no. 2, pp. F236-F244, 2004.
118. H. Koepsell, "Organic cation transporters in intestine, kidney, liver, and brain," Annual Review of Physiology, vol. 60, pp. 243-266, 1998.
119. H. Koepsell and H. Endou, "The SLC22 drug transporter family," Pflügers Archiv, vol. 447, no. 5, pp. 666-676, 2004.
120. D. Gründemann, J. Babin-Ebell, F. Martel, N. Örding, A. Schmidt, and E. Schömig, "Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells," Journal of Biological Chemistry, vol. 272, no. 16, pp. 10408-10413, 1997.
121. G. Ciarimboli and E. Schlatter, "Regulation of organic cation transport," Pflügers Archiv, vol. 449, no. 5, pp. 423-441, 2005.
122. C.-J. Lin, Y. Tai, M.-T. Huang et al., "Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents," Journal of Neurochemistry, vol. 114, no. 3, pp. 717-727, 2010.
123. D. Dickens, A. Owen, A. Alfirevic et al., "Lamotrigine is a substrate for OCT1 in brain endothelial cells," Biochemical Pharmacology, vol. 83, no. 6, pp. 805-814, 2012.
124. X. Wu, R. Kekuda, W. Huang et al., "Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain," The Journal of Biological Chemistry, vol. 273, no. 49, pp. 32776-32786, 1998.
125. X. Wu, R. L. George, W. Huang et al., "Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta," Biochimica et Biophysica Acta: Biomembranes, vol. 1466, no. 1-2, pp. 315-327, 2000.
126. A. Inano, Y. Sai, H. Nikaido et al., "Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2," Biopharmaceutics and Drug Disposition, vol. 24, no. 8, pp. 357-365, 2003.
127. A.-M. Lamhonwah, C. A. Ackerley, A. Tilups, V. D. Edwards, R. J. Wanders, and I. Tein, "OCTN3 is a mammalian peroxisomal membrane carnitine transporter," Biochemical and Biophysical Research Communications, vol. 338, no. 4, pp. 1966-1972, 2005.
128. I. Tamai, H. Yabuuchi, J.-I. Nezu et al., "Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1," The FEBS Letters, vol. 419, no. 1, pp. 107-111, 1997.
129. +-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance," Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 2, pp. 778-784, 1999.
130. J. M. Lauder, "Neurotransmitters as growth regulatory signals: role of receptors and second messengers," Trendsin Neurosciences, vol. 16, no. 6, pp. 233-240, 1993.
131. J. R. Mackey, R. S. Mani, M. Selner et al., "Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines," Cancer Research, vol. 58, no. 19, pp. 4349-4357, 1998.
132. J. H. Gray, R. P. Owen, and K. M. Giacomini, "The concentrative nucleoside transporter family, SLC28," Pflügers Archiv, vol. 447, no. 5, pp. 728-734, 2004.
133. M. A. Cabrita, S. A. Baldwin, J. D. Young, and C. E. Cass, "Molecular biology and regulation of nucleoside and nucle-obase transporter proteins in eukaryotes and prokaryotes," Biochemistry and Cell Biology, vol. 80, no. 5, pp. 623-638, 2002.
134. S. A. Baldwin, S. Y. M. Yao, R. J. Hyde et al., "Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes," The Journal of Biological Chemistry, vol. 280, no. 16, pp. 15880-15887, 2005.
135. C. Wang, W. Lin, H. Playa, S. Sun, K. Cameron, and J. K. Buolamwini, "Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4)," Biochemical Pharmacology, vol. 86, no. 11, pp. 1531-1540, 2013.
136. R. J. Hyde, C. E. Cass, J. D. Young, and S. A. Baldwin, "The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms," Molecular Membrane Biology, vol. 18, no. 1, pp. 53-63, 2001.
137. M. Sundaram, S. Y. M. Yao, J. C. Ingram et al., "Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs," Journal of Biological Chemistry, vol. 276, no. 48, pp. 45270-45275, 2001.
138. R. S. Mani, J. R. Hammond, J. M. J. Marjan et al., "Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes," The Journal of Biological Chemistry, vol. 273, no. 46, pp. 30818-30825, 1998.
139. C. R. Crawford, D. H. Patel, C. Naeve, and J. A. Belt, "Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line," The Journal of Biological Chemistry, vol. 273, no. 9, pp. 5288-5293, 1998.
140. K. Engel, M. Zhou, and J. Wang, "Identification and characterization of a novel monoamine transporter in the human brain," The Journal of Biological Chemistry, vol. 279, no. 48, pp. 50042-50049, 2004.
141. +/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics," The Journal of Biological Chemistry, vol. 280, no. 27, pp. 25436-25449, 2005.
142. H. Wolburg, K. Wolburg-Buchholz, J. Kraus et al., "Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme," Acta Neuropathologica, vol. 105, no. 6, pp. 586-592, 2003.
143. P. Dhawan, A. B. Singh, N. G. Deane et al., "Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer," The Journal of Clinical Investigation, vol. 115, no. 7, pp. 1765-1776, 2005.
144. W. Jia, R. Lu, T. A. Martin, and W. G. Jiang, "The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (review)," Molecular Medicine Reports, vol. 9, no. 3, pp. 779-785, 2014.
145. D. C. Davies, "Blood-brain barrier breakdown in septic encephalopathy and brain tumours," Journal of Anatomy, vol. 200, no. 6, pp. 639-646, 2002.
146. H. E. de Vries, M. C. M. Blom-Roosemalen, M. van Oosten et al., "The influence of cytokines on the integrity of the bloodbrain barrier in vitro," Journal of Neuroimmunology, vol. 64, no. 1, pp. 37-43, 1996.
147. K. Lamszus, N. O. Schmidt, S. Ergün, and M. Westphal, "Isolation and culture of human neuromicrovascular endothelial cells for the study of angiogenesis in vitro," Journal of Neuroscience Research, vol. 55, no. 3, pp. 370-381, 1999.
148. A. L. Cowles and J. D. Fenstermacher, "Theoretical considerations in the chemotherapy of brain tumors," in Antineoplastic and Immunosuppressive Agents Part I, A. C. Sartorelli and D. G. Johns, Eds., pp. 319-329, Springer, Berlin, Germany, 1974.
149. J. D. Fenstermacher and A. L. Cowles, "Theoretic limitations of intracarotid infusions in brain tumor chemotherapy," Cancer Treatment Reports, vol. 61, no. 4, pp. 519-526, 1977.
150. W. W. Eckman, C. S. Patlak, and J. D. Fenstermacher, "A critical evaluation of the principles governing the advantages of intra arterial infusions," Journal of Pharmacokinetics and Biopharmaceutics, vol. 2, no. 3, pp. 257-285, 1974.
151. J. Fenstermacher and J. Gazendam, "Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy," Cancer Treatment Reports, vol. 65, supplement 2, pp. 27-37, 1981.
152. Y. Hirano, K. Mineura, K. Mizoi, and N. Tomura, "Therapeutic results of intra-arterial chemotherapy in patients with malignant glioma," International Journal of Oncology, vol. 13, no. 3, pp. 537-542, 1998.
153. E. J. Dropcho, S. S. Rosenfeld, J. Vitek, B. L. Guthrie, and R. B. Morawetz, "Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas," Journal of Neuro-Oncology, vol. 36, no. 2, pp. 191-198, 1998.
154. S. Gundersen, K. Lote, and K. Watne, "A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas," European Journal of Cancer, vol. 34, no. 10, pp. 1565-1569, 1998.
155. H. A. Riina, J. F. Fraser, S. Fralin, J. Knopman, R. J. Scheff, and J. A. Boockvar, "Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma," Journal of Experimental Therapeutics and Oncology, vol. 8, no. 2, pp. 145-150, 2009.
156. R. G. Blasberg, C. S. Patlak, and W. R. Shapiro, "Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration," Cancer Treatment Reports, vol. 61, no. 4, pp. 633-641, 1977.
157. R. G. Blasberg, "Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion," Cancer Treatment Reports, vol. 61, no. 4, pp. 625-631, 1977.
158. R. G. Blasberg, "Pharmacodynamics and the blood-brain barrier," National Cancer Institute monograph, vol. 46, pp. 19-27, 1977.
159. D. R. Groothuis and R. M. Levy, "The entry of antiviral and antiretroviral drugs into the central nervous system," Journal of NeuroVirology, vol. 3, no. 6, pp. 387-400, 1997.
160. D. W. Laske, R. J. Youle, and E. H. Oldfield, "Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors," Nature Medicine, vol. 3, no. 12, pp. 1362-1368, 1997.
161. L. H. Parsons and J. B. Justice Jr., "Quantitative approaches to in vivo brain microdialysis," Critical Reviews in Neurobiology, vol. 8, no. 3, pp. 189-220, 1994.
162. E. C. M. De Lange, B. A. G. De Boer, and D. D. Breimer, "Microdialysis for pharmacokinetic analysis of drug transport to the brain," Advanced Drug Delivery Reviews, vol. 36, no. 2-3, pp. 211-227, 1999.
163. K. H. Dykstra, J. K. Hsiao, P. F. Morrison et al., "Quantitative examination of tissue concentration profiles associated with microdialysis," Journal of Neurochemistry, vol. 58, no. 3, pp. 931-940, 1992.
164. W. M. Pardridge, "Blood-brain barrier drug targeting: the future of brain drug development," Molecular Interventions, vol. 3, no. 2, pp. 90-51, 2003.
165. V. Chandramohan, J. H. Sampson, I. Pastan, and D. D. Bigner, "Toxin-based targeted therapy for malignant brain tumors," Clinical and Developmental Immunology, vol. 2012, Article ID 480429, 2012.
166. D. Fortin, C. Gendron, M. Boudrias, and M.-P. Garant, "Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis," Cancer, vol. 109, no. 4, pp. 751-760, 2007.
167. C. V. Borlongan and D. F. Emerich, "Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport," Brain Research Bulletin, vol. 60, no. 3, pp. 297-306, 2003.
168. K. Matsukado, T. Inamura, S. Nakano, M. Fukui, R. T. Bartus, and K. L. Black, "Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7," Neurosurgery, vol. 39, no. 1, pp. 125-134, 1996.
169. B. Erdlenbruch, V. Jendrossek, H. Eibl, and M. Lakomek, "Transient and controllable opening of the blood-brain barrier to cytostatic and antibiotic agents by alkylglycerols in rats," Experimental Brain Research, vol. 135, no. 3, pp. 417-422, 2000.
170. M. Kinoshita, N. McDannold, F. A. Jolesz, and K. Hynynen, "Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 31, pp. 11719-11723, 2006.
171. F. Leweke, M. S. Damian, C. Schindler, and W. Schachenmayr, "Multidrug resistance in glioblastoma. Chemosensitivity testing and immunohistochemical demonstration of P-glycoprotein," Pathology Research and Practice, vol. 194, no. 3, pp. 149-155, 1998.
172. L. A. Doyle and D. D. Ross, "Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)," Oncogene, vol. 22, no. 47, pp. 7340-7358, 2003.
173. S. F. Bates, C. Chen, R. Robey, M. Kang, W. D. Figg, and T. Fojo, "Reversal of multidrug resistance: lessons from clinical oncology," Novartis Foundation Symposia, vol. 243, pp. 83-185, 2002.
174. H. Thomas and H. M. Coley, "Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein," Cancer Control, vol. 10, no. 2, pp. 159-165, 2003.
175. R. Michael, A. Folkes, P. Ashworth et al., "Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives," Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 4, pp. 595-600, 1999.
176. A. H. Dantzig, R. L. Shepard, K. L. Law et al., "Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities," Journal of Pharmacology and Experimental Therapeutics, vol. 290, no. 2, pp. 854-862, 1999.
177. L. Van Zuylen, A. Sparreboom, A. Van Der Gaast et al., "The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel," Clinical Cancer Research, vol. 6, no. 4, pp. 1365-1371, 2000.
178. E. M. Kemper, A. E. van Zandbergen, C. Cleypool et al., "Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein," Clinical Cancer Research, vol. 9, no. 7, pp. 2849-2855, 2003.
179. G. Fricker and D. S. Miller, "Modulation of drug transporters at the blood-brain barrier," Pharmacology, vol. 70, no. 4, pp. 169-176, 2004.
180. R. G. Thorne, C. R. Emory, T. A. Ala, and W. H. Frey II, "Quantitative analysis of the olfactory pathway for drug delivery to the brain," Brain Research, vol. 692, no. 1-2, pp. 278-282, 1995.
181. D. Dhanda, W. Frey II, D. Leopold, and U. Kompella, "Approaches for drug deposition in the human olfactory epithelium," Drug Development & Delivery, vol. 5, pp. 64-72, 2005.
182. D. Wang, Y. Gao, and L. Yun, "Study on brain targeting of raltitrexed following intranasal administration in rats," Cancer Chemotherapy and Pharmacology, vol. 57, no. 1, pp. 97-104, 2006.
183. T. Sakane, S. Yamashita, N. Yata, and H. Sezaki, "Transnasal delivery of 5-fluorouracil to the brain in the rat," Journal of Drug Targeting, vol. 7, no. 3, pp. 233-240, 1999.
184. R. Hashizume, T. Ozawa, S. M. Gryaznov et al., "New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163," Neuro-Oncology, vol. 10, no. 2, pp. 112-120, 2008.
185. F. Wang, X. Jiang, and W. Lu, "Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats," International Journal of Pharmaceutics, vol. 263, no. 1-2, pp. 1-7, 2003.
186. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings," Advanced Drug Delivery Reviews, vol. 46, no. 1-3, pp. 3-26, 2001.
187. W. M. Pardridge, "Transport of small molecules through the blood-brain barrier: biology and methodology," Advanced Drug Delivery Reviews, vol. 15, no. 1-3, pp. 5-36, 1995.
188. D. R. Groothuis, B. E. Lippitz, I. Fekete et al., "The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma," Cancer Research, vol. 52, no. 20, pp. 5590-5596, 1992.
189. V. E. Shashoua and G. W. Hesse, "N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite," Life Sciences, vol. 58, no. 16, pp. 1347-1357, 1996.
190. M. O. Bradley, N. L. Webb, F. H. Anthony et al., "Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel," Clinical Cancer Research, vol. 7, no. 10, pp. 3229-3238, 2001.
191. M. E. Sherman, Y. S. Erozan, R. B. Mann et al., "Stereotactic brain biopsy in the diagnosis of malignant lymphoma," The American Journal of Clinical Pathology, vol. 95, no. 6, pp. 878-883, 1991.
192. T. Yoshikawa, T. Sakaeda, T. Sugawara, K. Hirano, and V. J. Stella, "A novel chemical delivery system for brain targeting," Advanced Drug Delivery Reviews, vol. 36, no. 2-3, pp. 255-275, 1999.
193. X.-H. Tian, X.-N. Lin, F. Wei et al., "Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles," International Journal of Nanomedicine, vol. 6, pp. 445-452, 2011.
194. A. Jain, G. Chasoo, S. K. Singh, A. K. Saxena, and S. K. Jain, "Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation," Journal of Microencapsulation, vol. 28, no. 1, pp. 21-28, 2011.
195. G. Huang, N. Zhang, X. Bi, and M. Dou, "Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity," International Journal of Pharmaceutics, vol. 355, no. 1-2, pp. 314-320, 2008.
196. Y. Ling, K. Wei, F. Zou, and S. Zhong, "Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma," International Journal of Pharmaceutics, vol. 430, no. 1-2, pp. 266-275, 2012.
197. D. S. Jain, R. B. Athawale, A. N. Bajaj et al., "Unraveling the cytotoxic potential of Temozolomide loaded into PLGA nanoparticles," DARU, Journal of Pharmaceutical Sciences, vol. 22, article 18, 2014.
198. C. Abrudan, I. S. Florian, A. Baritchii et al., "Assessment of temozolomide action encapsulated in chitosan and polymer nanostructures on glioblastoma cell lines," Romanian Neurosurgery, vol. 21, no. 1, pp. 18-29, 2014.
199. J. Tao, P. Hua-Nan, Y. Jin-Na et al., "Preparation and brain delivery evaluation of temozolomide-loaded albumin nanoparticles," Chinese Journal of Pharmaceuticals, vol. 44, no. 1, pp. 41-45, 2013.
200. D. A. Bota, A. Desjardins, J. A. Quinn, M. L. Affronti, and H. S. Friedman, "Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas," Therapeutics and Clinical Risk Management, vol. 3, no. 5, pp. 707-715, 2007.
201. 6-benzylguanine shell for glioma therapy," Biomaterials, vol. 34, no. 35, pp. 8968-8978, 2013.
202. Y.-C. Kuo and C.-T. Liang, "Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor," Biomaterials, vol. 32, no. 12, pp. 3340-3350, 2011.
203. C. Kang, X. Yuan, Y. Zhong et al., "Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D, L-lactic acid) nanoparticles," Technology in Cancer Research and Treatment, vol. 8, no. 1, pp. 61-70, 2009.
204. K. Fabel, J. Dietrich, P. Hau et al., "Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin," Cancer, vol. 92, no. 7, pp. 1936-1942, 2001.
205. Y.-C. Kuo and C.-T. Liang, "Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells," Colloids and Surfaces B: Biointerfaces, vol. 85, no. 2, pp. 131-137, 2011.
206. S. Wohlfart, A. S. Khalansky, S. Gelperina et al., "Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers," PLoS ONE, vol. 6, no. 5, Article ID e19121, 2011.
207. J. P. Wang, X. L. Zhu, Y. W. Xi, D. F. Wang, and G. H. Huang, "Preparation of lomustine loaded liposomes and studies of its pharmacokinetics and tissue distribution properties," Journal of Chinese Pharmaceutical Sciences, vol. 19, no. 5, pp. 353-362, 2010.
208. A. Y. Bedikian, N. E. Papadopoulos, K. B. Kim et al., "A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma," Melanoma Research, vol. 18, no. 6, pp. 400-404, 2008.
209. R. Saito, J. R. Bringas, T. R. McKnight et al., "Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging," Cancer Research, vol. 64, no. 7, pp. 2572-2579, 2004.
210. Q. Lv, L.-M. Li, M. Han et al., "Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome," International Journal of Pharmaceutics, vol. 444, no. 1-2, pp. 1-9, 2013.
211. A. Fiorillo, G. Maggi, N. Greco et al., "Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors," Journal of Neuro-Oncology, vol. 66, no. 1-2, pp. 179-185, 2004.
212. M. Wankhede, A. Bouras, M. Kaluzova, and C. G. Hadjipanayis, "Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy," Expert Review of Clinical Pharmacology, vol. 5, no. 2, pp. 173-186, 2012.
213. Y.-C. Kuo and T.-Y. Hong, "Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-HT-moduline," International Journal of Pharmaceutics, vol. 465, no. 1-2, pp. 132-142, 2014.
214. R. L. Juliano and D. Stamp, "Pharmacokinetics of liposome-encapsulated anti-tumor drugs: studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin," Biochemical Pharmacology, vol. 27, no. 1, pp. 21-27, 1978.
215. P.-Y. Chen, T. Ozawa, D. C. Drummond et al., "Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts," Neuro-Oncology, vol. 15, no. 2, pp. 189-197, 2013.
216. B. J. Turunen, H. Ge, J. Oyetunji et al., "Paclitaxel succinate analogs: anionic and amide introduction as a strategy to impart blood-brain barrier permeability," Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 22, pp. 5971-5974, 2008.
217. Y. Wang, C. Wang, C. Gong, G. Guo, F. Luo, and Z. Qian, "Polysorbate 80 coated poly (ε-caprolactone)-poly (ethylene glycol)-poly (ε-caprolactone) micelles for paclitaxel delivery," International Journal of Pharmaceutics, vol. 434, no. 1-2, pp. 1-8, 2012.
218. X.-Y. Li, Y. Zhao, M.-G. Sun et al., "Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma," Biomaterials, vol. 35, no. 21, pp. 5591-5604, 2014.
219. J. M. Provenzale, S. Mukundan, and M. Dewhirst, "The role of blood-brain barrier permeability in brain tumor imaging and therapeutics," American Journal of Roentgenology, vol. 185, no. 3, pp. 763-767, 2005.
220. J. Kreuter, "Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain," Journal of Nanoscience and Nanotechnology, vol. 4, no. 5, pp. 484-488, 2004.
221. Y. Jallouli, A. Paillard, J. Chang, E. Sevin, and D. Betbeder, "Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro," International Journal of Pharmaceutics, vol. 344, no. 1-2, pp. 103-109, 2007.
222. S. M. Moghimi, A. C. Hunter, and J. C. Murray, "Long-circulating and target-specific nanoparticles: theory to practice," Pharmacological Reviews, vol. 53, no. 2, pp. 283-318, 2001.
223. W. M. Pardridge, "Vector-mediated drug delivery to the brain," Advanced Drug Delivery Reviews, vol. 36, no. 2-3, pp. 299-321, 1999.
224. V. Soni, D. V. Kohli, and S. K. Jain, "Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain," Journal of Drug Targeting, vol. 16, no. 1, pp. 73-78, 2008.
225. A. Doi, S. Kawabata, K. Iida et al., "Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy," Journal of Neuro-oncology, vol. 87, no. 3, pp. 287-294, 2008.
226. X. Ying, H. Wen, W.-L. Lu et al., "Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals," Journal of Controlled Release, vol. 141, no. 2, pp. 183-192, 2010.
227. B. Gupta, T. S. Levchenko, and V. P. Torchilin, "TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice," Oncology Research, vol. 16, no. 8, pp. 351-359, 2007.
228. L. Juillerat-Jeanneret, "Critical analysis of cancer therapy using nanomaterials," in Nanotechnologies for the Life Sciences, Wiley-VCH, 2007.
229. L. Fenart, A. Casanova, B. Dehouck et al., "Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier," Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 3, pp. 1017-1022, 1999.
230. D. Wu and W. M. Pardridge, "Blood-brain barrier transport of reduced folic acid," Pharmaceutical Research, vol. 16, no. 3, pp. 415-419, 1999.
231. B. Petri, A. Bootz, A. Khalansky et al., "Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants," Journal of Controlled Release, vol. 117, no. 1, pp. 51-58, 2007.
232. Y. Tsutsui, K. Tomizawa, M. Nagita et al., "Development of bionanocapsules targeting brain tumors," Journal of Controlled Release, vol. 122, no. 2, pp. 159-164, 2007.
233. H. L. Wong, R. Bendayan, A. M. Rauth, Y. Li, and X. Y. Wu, "Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles," Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 491-504, 2007.
234. H. Chen, X. Zhang, S. Dai et al., "Multifunctional gold nanostar conjugates for tumor imaging and combined photothermal and chemo-therapy," Theranostics, vol. 3, no. 9, pp. 633-649, 2013.
235. W.-H. Chen, X.-D. Xu, H.-Z. Jia et al., "Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo," Biomaterials, vol. 34, no. 34, pp. 8798-8807, 2013.
236. Z. Liu and X.-J. Liang, "Nano-carbons as theranostics," Theranostics, vol. 2, no. 3, pp. 235-237, 2012.
237. S.-Y. Qin, J. Feng, L. Rong et al., "Theranostic GO-based nanohybrid for tumor induced imaging and potential combinational tumor therapy," Small, vol. 10, no. 3, pp. 599-608, 2014.
238. K. K. Jain, "Use of nanoparticles for drug delivery in glioblastoma multiforme," Expert Review of Neurotherapeutics, vol. 7, no. 4, pp. 363-372, 2007.
239. A. V. Kabanov, E. V. Batrakova, and D. W. Miller, "Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier," Advanced Drug Delivery Reviews, vol. 55, no. 1, pp. 151-164, 2003.
240. E. V. Batrakova and A. V. Kabanov, "Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers," Journal of Controlled Release, vol. 130, no. 2, pp. 98-106, 2008.
241. R. S. Dhanikula, A. Argaw, J.-F. Bouchard, and P. Hildgen, "Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability," Molecular Pharmaceutics, vol. 5, no. 1, pp. 105-116, 2008.
242. C. M. Kramm, N. G. Rainov, M. Sena-Esteves et al., "Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors," Human Gene Therapy, vol. 7, no. 3, pp. 291-300, 1996.
243. J. Chen, T. Bezdek, J. Chang et al., "A glial-specific, repressible, adenovirus vector for brain tumor gene therapy," Cancer Research, vol. 58, no. 16, pp. 3504-3507, 1998.
244. H. E. J. Hofland, D. Nagy, J.-J. Liu et al., "In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex," Pharmaceutical Research, vol. 14, no. 6, pp. 742-749, 1997.
245. S.-S. Kim, A. Rait, E. Kim et al., "Nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival," ACS Nano, vol. 8, no. 6, pp. 5494-5514, 2014.
246. A. Schuessler, C. Smith, L. Beagley et al., "Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma," Cancer Research, vol. 74, no. 13, pp. 3466-3476, 2014.
247. A. M. Thayer, "Improving peptides," Chemical & Engineering News Archive, vol. 89, no. 22, pp. 13-20, 2011.
248. L. Soroceanu, Y. Gillespie, M. B. Khazaeli, and H. Sontheimer, "Use of chlorotoxin for targeting of primary brain tumors," Cancer Research, vol. 58, no. 21, pp. 4871-4879, 1998.
249. M. Z. Strowski and A. D. Blake, "Function and expression of somatostatin receptors of the endocrine pancreas," Molecular and Cellular Endocrinology, vol. 286, no. 1-2, pp. 169-179, 2008.
250. K. De, A. Bhowmik, A. Behera, I. Banerjee, M. K. Ghosh, and M. Misra, "Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy," Journal of Peptide Science, vol. 18, no. 12, pp. 720-730, 2012.
251. R. A. Henderson, S. Mossman, N. Nairn, and M. A. Cheever, "Cancer vaccines and immunotherapies: emerging perspectives," Vaccine, vol. 23, no. 17-18, pp. 2359-2362, 2005.
252. R. A. Fenstermaker and M. J. Ciesielski, "Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma," Expert Review of Vaccines, vol. 13, no. 3, pp. 377-385, 2014.
253. J. H. Sampson, G. E. Archer, D. A. Mitchell et al., "An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme," Molecular Cancer Therapeutics, vol. 8, no. 10, pp. 2773-2779, 2009.
254. L. W. Xu, K. K. H. Chow, M. Lim, and G. Li, "Current vaccine trials in glioblastoma: a review," Journal of Immunology Research, vol. 2014, Article ID 796856, 10 pages, 2014.
255. R. J. Boado, "Blood-brain barrier transport of non-viral gene and RNAi therapeutics," Pharmaceutical Research, vol. 24, no. 9, pp. 1772-1787, 2007.
256. N. Shi and W. M. Pardridge, "Noninvasive gene targeting to the brain," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7567-7572, 2000.
257. W. M. Pardridge, "Gene targeting in vivo with pegylated immunoliposomes," Methods in Enzymology, vol. 373, pp. 507-528, 2003.
258. Y. Zhang, Y.-F. Zhang, J. Bryant, A. Charles, R. J. Boado, and W. M. Pardridge, "Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer," Clinical Cancer Research, vol. 10, no. 11, pp. 3667-3677, 2004.
259. K. J. Lim, S. Bisht, E. E. Bar, A. Maitra, and C. G. Eberhart, "A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors," Cancer Biology and Therapy, vol. 11, no. 5, pp. 464-473, 2011.
260. T. Kato, A. Natsume, H. Toda et al., "Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells," Gene Therapy, vol. 17, no. 11, pp. 1363-1371, 2010.
261. C.-H. Wang, S.-H. Chiou, C.-P. Chou, Y.-C. Chen, Y.-J. Huang, and C.-A. Peng, "Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 7, no. 1, pp. 69-79, 2011.